Karyopharm's Q1 2026: Promising Myelofibrosis Data, Endometrial Cancer Trial Wraps

Karyopharms Q1 2026 earnings showcase solid progress, with total revenue up to $35.1M, driven by $29.2M in U.S. XPOVIO sales. They reaffirm full-year guidance and maintain cash on hand. The highlight is the SENTRY trials top-line data, showing significant spleen volume reduction and promising survival signals in myelofibrosis. Karyopharm plans to leverage their multiple myeloma base to expand into myelofibrosis and endometrial cancer. The EC-zero four two trial for endometrial cancer has completed enrollment, with top-line data expected mid-2026. Theyre preparing for FDA talks, ASCO presentation, and compendia inclusion to drive use. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/76ebecd94a3c3887